arrow
C

Chiara Cassani

University of Pavia
H指数:19
被引数:1,188

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Clinical and molecular heterogeneity in advanced-stage POLE-mutated endometrial carcinoma: a focus on aggressive subsets and co-mutations

POLE突变晚期子宫内膜癌的临床和分子异质性:聚焦于侵袭性亚组和共突变

2026-04-290
OA
Final overall survival (OS) results from the phase 3 ROSELLA trial: Relacorilant plus nab-paclitaxel vs nab-paclitaxel monotherapy in patients with platinum-resistant ovarian cancer (PROC) (GOG-3073, ENGOT-ov72, APGOT-Ov10, and LACOG-0223)

ROSELLA三期试验的最终总生存期(OS)结果:relacorilant联合nab-紫杉醇对比nab-紫杉醇单药治疗铂耐药卵巢癌(PROC)患者的疗效(GOG-3073,ENGOT-ov72,APGOT-Ov10和LACOG-0223)

2026-04-230
PRE
Letrozole for hormone receptor-positive low-grade ovarian cancer: Preliminary toxicity results of a phase III trial

来曲唑用于激素受体阳性低级别卵巢癌:一项III期试验的初步毒性结果

2025-12-010
PRE
Quality of life and satisfaction with ospemifene for treating vulvovaginal atrophy in breast cancer survivors: six-month results from the PatiEnt satisfactiON studY (PEONY)

生活质量和对奥斯培米芬治疗乳腺癌幸存者外阴阴道萎缩的满意度:PEONY试验(PatiEnt satisfactiON studY)六个月结果

2025-08-070
PREAI
Benefit from maintenance with PARP inhibitor in newly diagnosed ovarian cancer according to BRCA1/2 mutation type and site: a multicenter real-world study

根据BRCA1/2突变类型和位点,在新诊断卵巢癌患者中从PARP抑制剂维持治疗中获益:一项多中心真实世界研究

2025-04-011
OAAI
The Role Of POLE Mutational Status In Endometrial Cancer: A MITO POLE-END Observational Study

POLE突变状态在子宫内膜癌中的作用:一项MITO POLE-END观察性研究

2025-02-010
PRE
Niraparib In Patients With No Residual Disease After Primary Surgery: Preliminary Results Of The MITO 40 Study

尼拉帕利在主要手术后无残留疾病患者中的应用:MITO 40研究的初步结果

2025-02-010
PRE
Menopause and endometriosis

绝经和子宫内膜异位症

2024-12-011
OAAI